Lantheus Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
July 28, 2021 at 07:51 am EDT
Share
Lantheus Holdings, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 101.064 million compared to USD 66.010 million a year ago. Operating loss was USD 26.781 million compared to USD 5.545 million a year ago. Net loss was USD 26.657 million compared to USD 7.012 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.16 a year ago. For the half year, sales was USD 193.573 million compared to USD 156.714 million a year ago. Operating loss was USD 11.159 million compared to operating Income of USD 1.580 million a year ago. Net loss was USD 17.649 million compared to USD 3.675 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.09 a year ago.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
LANTHEUS HOLDINGS, INC. 
